D. Boral Capital Reiterates “Buy” Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a report issued on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.

Several other research analysts also recently weighed in on the company. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. BTIG Research started coverage on ImmunityBio in a research note on Friday, January 10th. They issued a “buy” rating and a $6.00 target price for the company.

ImmunityBio Price Performance

ImmunityBio stock opened at $3.08 on Monday. The stock has a market capitalization of $2.15 billion, a P/E ratio of -3.35 and a beta of 0.86. ImmunityBio has a 12-month low of $2.28 and a 12-month high of $10.53. The firm’s 50-day moving average is $3.43 and its two-hundred day moving average is $4.03.

Institutional Trading of ImmunityBio

Institutional investors have recently made changes to their positions in the stock. Stephens Inc. AR purchased a new stake in ImmunityBio during the fourth quarter valued at about $26,000. Captrust Financial Advisors acquired a new stake in ImmunityBio during the 3rd quarter worth approximately $41,000. Mutual Advisors LLC purchased a new position in ImmunityBio in the fourth quarter valued at approximately $41,000. Virtu Financial LLC acquired a new position in ImmunityBio during the third quarter valued at approximately $51,000. Finally, Algert Global LLC acquired a new stake in shares of ImmunityBio in the second quarter worth $86,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.